News Sentiment

SNDX sentiment intelligence

Syndax Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.61 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+8.2% over one week, +29.4% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 8.2% Price confirming higher
Trend fit Trend inactive 29.4% over four weeks
Fair value 32.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 31
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 11
simplywall.st 6
TradingView 5
MarketBeat 4
GlobeNewswire 3
Seeking Alpha 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 12
Analyst action 3
Regulatory and legal 2
Deals and strategy 1
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
MarketBeat Direct company coverage

Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright

HC Wainwright has reiterated a "buy" rating on Syndax Pharmaceuticals (NASDAQ:SNDX), setting a $40 price target which suggests a 65.8% upside. The company reported better-than-expected quarterly EPS of ($0.48) and a significant year-over-year revenue increase of 224.3%, although

Tone
Positive 66/100
Event
Earnings
Published
15 Jul 2026 12:46
Source
MarketBeat
Investing.com Direct company coverage

H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy

H.C. Wainwright reiterated a Buy rating and a $40.00 price target for Syndax Pharmaceuticals (NASDAQ:SNDX) after the company's research and development day. The analyst firm highlighted two new assets, SNDX-62122 and SNDX-4321, with SNDX-62122 showing promise as a next-generation

Tone
Positive 81/100
Event
Analyst action
Published
15 Jul 2026 12:46
Source
Investing.com
TradingView Direct company coverage

SNDX6417984 Bond Coupon Profile — Rate & Payments

This article provides a bond coupon profile for Syndax Pharmaceuticals, Inc. (SNDX6417984). It indicates a current coupon rate of 2.25% with the next interest payment scheduled for December 15, 2026. The profile offers an overview of the bond's interest payments and redemption de

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 03:46
Source
TradingView
TradingView Direct company coverage

SNDX6417984 Bond Profile — Key Metrics

This article provides key metrics for the Syndax Pharmaceuticals, Inc. 2.25% 15-JUN-2031 bond, identified as SNDX6417984 FINRA. It details the bond's issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. Additionally, it gives a

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 21:14
Source
TradingView
Market source Direct company coverage

Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push

Syndax Pharmaceuticals is expanding its pipeline beyond its approved drugs Revuforj and Niktimvo, focusing on new indications in myelofibrosis and EGFR-mutated non-small cell lung cancer. The company plans a proof-of-principle trial for Revuforj in myelofibrosis and is advancing

Tone
Positive 71/100
Event
Market update
Published
14 Jul 2026 20:14
Source
Market source
Seeking Alpha Direct company coverage

Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - Slideshow (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc. (SNDX) has published a slide deck discussing its pipeline expansion and the next phase of innovation for its lead therapies. This information was shared in conjunction with an event, indicating a focus on future development and strategic direction for

Tone
Positive 67/100
Event
Market update
Published
14 Jul 2026 16:40
Source
Seeking Alpha
Yahoo! Finance Canada Direct company coverage

Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet

Wall Street analysts project Syndax Pharmaceuticals (SNDX) could see a 70.38% surge, with a mean price target of $39. While price targets alone can be misleading, strong agreement among analysts on higher earnings estimates and a Zacks Rank #2 (Buy) suggest a potential upside. In

Tone
Positive 72/100
Event
Earnings
Published
14 Jul 2026 13:40
Source
Yahoo! Finance Canada
TradingView Direct company coverage

SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027

Syndax Pharmaceuticals (SNDX) is expanding its pipeline with new EGFR and menin inhibitors and advancing late-stage programs in leukemia, GVHD, and IPF. The company anticipates multiple clinical milestones through 2027, supported by strategic partnerships and a strong financial s

Tone
Positive 80/100
Event
Market update
Published
14 Jul 2026 12:40
Source
TradingView
Stock Titan Direct company coverage

Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts

Syndax Pharmaceuticals (NASDAQ: SNDX) has outlined its expanded pipeline and clinical development plans for 2026-2027, including new assets SNDX-4321 for EGFR-mutated NSCLC and SNDX-62122 for myelofibrosis. The company also highlighted the commercial success of its FDA-approved d

Tone
Positive 66/100
Event
Market update
Published
14 Jul 2026 12:40
Source
Stock Titan
GlobeNewswire Direct company coverage

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Syndax Pharmaceuticals is hosting an R&D Event to showcase its late-stage programs and introduce new pipeline assets, SNDX-4321 for NSCLC and SNDX-62122 for MF. The company aims to expand its leadership in menin and CSF-1R inhibition, building on recent successes with Revuforj an

Tone
Positive 76/100
Event
Market update
Published
14 Jul 2026 11:40
Source
GlobeNewswire
Stock Titan Direct company coverage

Syndax Adds Two Pipeline Assets for Lung Cancer and Myelofibrosis

Syndax Pharmaceuticals announced two new pipeline assets, SNDX-4321 for EGFR-mutated non-small cell lung cancer (NSCLC) and SNDX-62122 for myelofibrosis (MF), during its R&D event. SNDX-4321, a novel EGFR inhibitor, is expected to have an IND submission by year-end 2026 and a Pha

Tone
Positive 67/100
Event
Market update
Published
14 Jul 2026 11:40
Source
Stock Titan
Stock Traders Daily Direct company coverage

Technical Reactions to SNDX Trends in Macro Strategies

This article provides a technical analysis of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting strong sentiment across all time horizons and an exceptional 52.6:1 risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk

Tone
Positive 81/100
Event
Market update
Published
10 Jul 2026 01:42
Source
Stock Traders Daily
Investing.com Nigeria Direct company coverage

Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com

This article from Investing.com announces a Form 4 filing for Syndax Pharmaceuticals, dated July 9th. The filing pertains to stock market activity for the company, whose stock symbol is SNDX. The brief entry reiterates the date and company information.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 22:09
Source
Investing.com Nigeria
MarketBeat Direct company coverage

Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares

Syndax Pharmaceuticals CEO Michael Metzger sold 32,375 shares of SNDX stock on July 8th for approximately $784,770, reducing his stake by 6.26%. Despite the insider sale, the stock rose 1.1% to $24.84, nearing its 52-week high, and analysts maintain a "Moderate Buy" consensus wit

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jul 2026 21:41
Source
MarketBeat
Stock Titan Direct company coverage

Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan

Syndax Pharmaceuticals CEO Michael A. Metzger exercised stock options for 32,375 shares at $6.38 each and subsequently sold all 32,375 shares on the open market at an average price of $24.2402 per share. These transactions were executed under a pre-established Rule 10b5-1 trading

Tone
Negative 40/100
Event
Market update
Published
09 Jul 2026 21:41
Source
Stock Titan
Moomoo Direct company coverage

Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing

An insider at Syndax Pharmaceuticals recently sold shares worth $784,776, as detailed in a recent SEC filing. The sale involved 31,500 shares at an average price of $24.91 per share. This transaction increases transparency regarding insider activity at the company.

Tone
Negative 39/100
Event
Market update
Published
09 Jul 2026 21:09
Source
Moomoo
Investing.com Canada Direct company coverage

Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com

This article from Investing.com reports on a Form 144 filing for Syndax Pharmaceuticals (SNDX) for July 8, 2026. The brief piece indicates that shares of Syndax Pharmaceuticals were up 5.68% at the time of publication, suggesting market interest stemming from the filing.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:10
Source
Investing.com Canada
Stock Titan Direct company coverage

SNDX insider files to sell 32,375 shares (NASDAQ: SNDX)

A Form 144 filing indicates a proposed sale of 32,375 shares of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) common stock on July 8, 2026, through the exercise of stock options. The filing also disclosed a previous sale of 6,847 shares on June 1, 2026, for $130,024.53. The transacti

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:10
Source
Stock Titan
Simply Wall Street Direct company coverage

Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next

Syndax Pharmaceuticals (SNDX) experienced a 6.3% increase in stock value despite being removed from several Russell value indexes on June 27, 2026. This removal primarily impacts the stock's ownership structure and trading patterns due to benchmark-driven portfolio rebalancing, r

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 09:10
Source
Simply Wall Street
AD HOC NEWS Direct company coverage

Syndax Pharmaceuticals holds steady as investors await a fresh catalyst

Syndax Pharmaceuticals (SNDX) stock is holding steady with no immediate new market-moving filings, shifting focus to its US-listed setup and pipeline. The company, a US biotech firm specializing in oncology and hematology, relies heavily on clinical data, regulatory milestones, a

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 12:40
Source
AD HOC NEWS
MarketBeat Direct company coverage

SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

SG Americas Securities LLC reduced its stake in Syndax Pharmaceuticals by 70.2% in Q1, now holding 38,548 shares worth $900,000. Despite this, the company has an average "Moderate Buy" rating, although some analysts like Weiss Ratings maintain a "sell." Recent insider selling by

Tone
Negative 37/100
Event
Analyst action
Published
06 Jul 2026 09:11
Source
MarketBeat
Simply Wall Street Direct company coverage

Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?

Syndax Pharmaceuticals (SNDX) recently released encouraging Phase 1/2 data for its Revuforj combination regimen in acute myeloid leukemia, showing high response rates and attracting investor interest. Despite a significant one-year share price return, the stock is trading below a

Tone
Positive 70/100
Event
Macro sensitivity
Published
04 Jul 2026 20:40
Source
Simply Wall Street
GlobeNewswire Direct company coverage

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals announced inducement grants to eight new employees for up to 250,700 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a portion vesting on the one-year anniversary and the remainder monthly thereafte

Tone
Positive 65/100
Event
Market update
Published
02 Jul 2026 07:09
Source
GlobeNewswire
MarketBeat Direct company coverage

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts

Syndax Pharmaceuticals (NASDAQ:SNDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $42.55. Recent analyst updates include price target increases from JPMorgan, Barclays, and Goldman Sachs, though Wall Street Zen downgraded

Tone
Positive 63/100
Event
Analyst action
Published
01 Jul 2026 06:09
Source
MarketBeat
TradingView Direct company coverage

Purchase/sale of business (net) of Syndax Pharmaceuticals Inc – SWB:1T3

This article provides financial information for Syndax Pharmaceuticals Inc, listed on the Stuttgart Stock Exchange under the ticker SWB:1T3. It specifically highlights the "Purchase/sale of business (net)" data, indicating that currently, there are no recorded values for this met

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 08:40
Source
TradingView